The interaction of immunoglobulin E and otherwise harmless antigens (allergens) leadsin sensitized individuals through effector cell activation to the immediate induction of acascade of inflammatory reactions, the hallmark of type I allergy. Recently, the molecularand structural characterization of allergens, specific IgE antibodies and their epitopes hasmade rapid progress. Here we discuss active and passive strategies for therapy of type Iallergy, which are based on interfering with the IgE–allergen interaction.

1.
Kay AB: Allergy and Allergic Diseases. Oxford; Blackwell Science,1997.
2.
Van–Neerven RJ, van de Pol MM, Wierenga EA, AalberseRC, Jansen HM, Kapsenberg ML: Peptide specificity and HLA restriction do not dictatelymphokine production by allergen–specific T lymphocyte clones. Immunology1994;82:351–356.
3.
Ebner C, Schenk S, Najafian N, Siemann U, Steiner R, Fischer GW,Hoffmann K, Szepfalusi Z, Scheiner O, Kraft D: Nonallergic individuals recognize the same Tcell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol1995;154:1932– 1940.
4.
Saint–Remy JM, Lebrun PM, Lebecque SJ, Masson PL:Human immune response to allergens of house dust mite, Dermatophagoides pteronyssinus.Isotypic analysis of antibodies in atopic and non–atopic subjects. Allergy1988;43:338–347.
5.
Segal DM, Taurog JD, Metzger H: Dimeric immunoglobulin E servesas a unit signal for mast cell degranulation. Proc Natl Acad Sci USA1977;74:2993–2997.
6.
Valenta R, Kraft D: Recombinant allergens for diagnosis and therapyof allergic diseases. Curr Opin Immunol 1995;7:751–756.
7.
Valenta R, Steinberger P, Duchêne M, Kraft D: Immunologicalsimilarities among allergens: Prerequisite for a specific and component based therapy ofallergy. Immunol Cell Biol 1996;74:187–194.
8.
Valenta R, Vrtala S, Laffer S, Spitzauer S, Kraft D: Recombinantallergens. Allergy, in press.
9.
Norman PS: Modern concepts of immunotherapy. Curr Opin Immunol1993;5:968–973.
10.
Sheffer AL: Allergen–specific immunotherapy: A role forT–cell anergy. Ann Allergy 1993;71: 327–329.
11.
Yssel H, Fasler S, Lamb J, de Vries JE: Induction ofnon–responsiveness in human allergen–specific type 2 T helper cells. CurrOpin Immunol 1994;6:847–852.
12.
Braden BC, Poljak RJ: Structural features of the reactions betweenantibodies and protein antigens. FASEB J 1995;9:9–16.
13.
Geysen HM, Rodda SJ, Mason TJ, Tribbick G, Schoofs PG:Strategies for epitope analysis using peptide synthesis. J Immunol Methods1987;102:259–274.
14.
van t Hof W, Driedijk PC, van den Berg M, Beck–SickingerAG, Jung G, Aalberse RC: Epitope mapping of the Dermatophagoides pteronyssinus housedust mite major allergen Der p 2 using overlapping synthetic peptides. Mol Immunol1991;28:1225–1232.
15.
Ball G, Shelton MJ, Walsh BJ, Hill DJ, Hosking CS, Howden ME: Amajor continuous allergenic epitope of bovine beta–lactoglobulin recognized byhuman IgE binding. Clin Exp Allergy 1994;24:758–764.
16.
Ball T, Vrtala S, Sperr WR, Valent P, Susani M, Kraft D, Valenta R:Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. J BiolChem 1994;269: 28323–28328.
17.
Collins SP, Ball G, Vonarx E, Hosking C, Shelton M, Hill D, HowdenME: Absence of continuous epitopes in the house dust mite major allergens Der p 1 fromDermatophagoides pteronyssinus and Der f 1 from Dermatophagoides farinae. Clin ExpAllergy 1996;26: 36–42.
18.
Greene WK, Cyster JG, Chua KY, O’Brien RM, Thomas WR:IgE and IgG binding of peptides expressed from fragments of cDNA encoding the majorhouse dust mite allergen Der p I. J Immunol 1991;147:3768–3773.
19.
Ong EK, Knox RB, Singh MB: Mapping of the antigenic andallergenic epitopes of Lol p VB using gene fragmentation. Mol Immunol 1995;32:295–302.
20.
Schneider T, Lang AB, Carballido JM, Santamaria–Babi LF,Dudler T, Kagi MK, Blaser K, Suter M: Human monoclonal or polyclonal antibodies recognizepredominantly discontinuous epitopes on the bee venom phospholipase A2. J Allergy ClinImmunol 1994;94:61–70.
21.
Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, SperrWR, Valent P, Ebner C, Kraft D, Valenta R: Conversion of the major birch pollen allergen,Bet v 1, into two nonanaphylactic T cell epitope–containing fragments. Candidates fora novel form of specific immunotherapy. J Clin Invest 1997;99:1673– 1681.
22.
Seiberler S, Scheiner O, Kraft D, Lonsdale D, Valenta R:Characterization of a birch pollen allergen, Bet v III, representing a novel class ofCa2+ binding proteins; specific expression in mature pollen anddependence of patients IgE–binding on protein bound Ca2+. EMBOJ 1994; 13:3481–3486.
23.
Twardosz A, Hayek B, Seiberler S, Vangelista L, Elfman L,Grönlund H, Kraft D, Valenta R: Molecular characterization, expression in Escherichiacoli, and epitope analysis of a two EF–hand calcium–binding birch pollenallergen, Bet v 4. Biochem Biophys Res Commun 1997;239:197–204.
24.
Engel E, Richter K, Obermeyer G, Briza P, Kungl AJ, Simon B, AuerM, Ebner C, Rheinberger HJ, Breitenbach M, Ferreira F: Immunological and biologicalproperties of Bet v 4, a novel birch pollen allergen with two EF–handcalcium–binding domains. J Biol Chem 1997;272:28630–28637.
25.
Zeiler T, Taivainen A, Rytkönen M, Rautiainen J, Karjalainen H,Mäntyjärvi R, Tuomisto L, Virtanen T: Recombinant allergen fragments ascandidate preparations for allergen immunotherapy. J Allergy Clin Immunol 1997;100:721–727.
26.
Gershoni JM, Stern B, Denisova G: Combinatorial libraries, epitopestructure and the prediction of protein conformations. Immunol Today1997;18:108–110.
27.
Lebecque S, Dolecek C, Laffer S, Visco V, Denepoux S, Pin JJ,Guret C, Boltz–Nitulescu G, Weyer A, Valenta R: Immunologic characterization ofmonoclonal antibodies that modulate human IgE binding to the major birch pollen allergenBet v 1. J Allergy Clin Immunol 1997;99:374–384.
28.
Gajhede M, Osmark P, Poulsen FM, Ipsen H, Larsen JN, Joost vanNeerven RJ, Schou C, Lowenstein H, Spangfort MD: X–ray and NMR structure of Betv 1, the origin of birch pollen allergy. Nat Struct Biol 1996;3:1040– 1045.
29.
Fedorov AA, Ball T, Mahoney NM, Valenta R, Almo SC: Themolecular basis for allergen cross–reactivity: Crystal structure and IgE–epitopemapping of birch pollen profilin. Structure 1997;5:33–45.
30.
Fedorov AA, Ball T, Valenta R, Almo SC: X–ray crystalstructures of birch pollen profilin and Phl p 2. Int Arch Allergy Immunol 1997;113:109–113.
31.
Bufe A, Betzel C, Schramm G, Petersen A, Becker WM, Schlaak M,Perbandt M, Dauter Z, Weber W: Crystallization and preliminary diffraction data of a majorpollen allergen. Crystal growth separates a low molecular weight form with elevatedbiological activity. J Biol Chem 1996;271:27193–27196.
32.
Müller GA, Smith AM, Williams DC Jr, Hakkaart GA, AalberseRC, Chapman MD, Rule GS, Benjamin DC: Expression and secondary structuredetermination by NMR methods of the major house dust mite allergen Der p 2. J Biol Chem1997;272:26893–26898.
33.
Thorn KS, Christensen HEM, Shigeta R Jr, Huddler D, Shalaby L,Lindberg U, Chua NH, Schutt CE: The crystal structure of a major allergen from plants.Structure 1997;5:19–32.
34.
Valenta R, Duchêne M, Pettenburger K, Sillaber C, Valent P,Bettelheim P, Breitenbach M, Rumpold H, Kraft D, Scheiner O: Identification of profilin as anovel pollen allergen; IgE autoreactivity in sensitized individuals. Science1991;253:557–560.
35.
Valenta R, Duchêne M, Ebner C, Valent P, Sillaber C, DevillerP, Ferreira F, Tejkl M, Edelmann H, Kraft D, Scheiner O: Profilins constitute a novel familyof functional plant pan–allergens. J Exp Med 1992;175:377–385.
36.
Schutt CE, Myslik JC, Rozycki MD, Goonesekere NCW, Lindberg U:The structure of crystalline profilin–β–actin. Nature 1993;365:810–816.
37.
Domke T, Federau T, Schlüter K, Giehl K, Valenta R,Schomburg D, Jockusch BM: Birch pollen profilin: Structural organization and interaction withpoly–(L–proline) peptides as revealed by NMR. FEBS Lett1997;411:291– 295.
38.
Steinberger P, Kraft D, Valenta R: Construction of a combinatorialIgE library from an allergic patient: Isolation and characterization of human IgE Fabs withspecificity for the major timothy grass pollen allergen, Phl p 5. J Biol Chem1996;271:10967–10972.
39.
deWeck AL, Jeunet F, Schulz KH, Louis P, Girard JP, Grilliat JP,Moneret–Vautrin D, Storck H, Wüthrich B, Spengler H, Juhlin L, Scheiffarth F,Warnatz H, Wortmann F, Virgaay SRN: Clinical trial of Ro 6–0787, a monovalentspecific hapten inhibitor of penicillin allergy. Z Immunitätsforsch1975;150:138–160.
40.
Richter W, Hedin H, Kraft D, Messmer K: Anaphylactoid reactionsafter dextran II. Experimental studies in animals on the principle of hapten inhibition. BeitrInfusionsther Klin Ernähr 1981;8:54–65.
41.
Niederberger V, Pauli G, Grönlund H, Fröschl R,Rumpold H, Kraft D, Valenta R, Spitzauer S: Recombinant birch pollen allergens (rBet v 1,rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel and oakpollen. A quantitative IgE inhibition study using sera from different populations. J Allergy ClinImmunol 1998;in press.
42.
Niederberger V, Laffer S, Fröschl R, Kraft D, Rumpold H,Kapiotis S, Valenta R, Spitzauer S: IgE antibodies to recombinant pollen allergens (Phl p 1,Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen–specificIgE. J Allergy Clin Immunol 1998; 101:258–264.
43.
Tanabe S, Tesaki S, Yanagihara Y, Mita H, Takahashi K, Arai S,Watanabe M: Inhibition of basophil histamine release by a haptenic peptide mixture preparedby chymotryptic hydrolysis of wheat fluor. Biochem Biophys Res Commun1996;223:492–495.
44.
Daeron M, Malbec O, Latour S, Arock M, Fridman WH: Regulation ofhigh–affinity IgE receptor–mediated mast cell activation by murinelow–affinity IgG receptors. J Clin Invest 1995;95:577–585.
45.
Cooke RA, Bernhard JH, Hebald S, Stull A: Serological evidence ofimmunity with co–existing sensitization in hay fever type of human allergy. J Exp Med1935;62:733–750.
46.
Loveless MH: Immunological studies of pollinosis. I. The presence oftwo antibodies related to the same pollen–antigen in serum of treated hay feverpatients. J Immunol 1940;38:25–50.
47.
Visco V, Dolecek C, Denepoux S, Mao JL, Guret C, Rousset F,Guinnepain MT, Kraft D, Valenta R, Weyer A, Banchereau J, Lebecque S: Human IgGmonoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. JImmunol 1996;157:956–962.
48.
Valenta R, Flicker S, Eibensteiner PB, Laffer S, Steinberger P, KraftD: Recombinant allergen fragments: Tools for diagnosis, prevention and therapy of type Iallergy. Biol Chem 1997; 378:745–748.
49.
Gram H, Marconi LA, Barbas CF III, Collet TA, Lerner RA, Kang AS:In vitro selection and affinity maturation of antibodies from a naive combinatorialimmunoglobulin library. Proc Natl Acad Sci USA 1992;89:3576–3580.
50.
Lichtenstein LM, Holtzman NA, Burnett LS: A quantitative in vitrostudy of the chromatographic distribution and immunoglobulin characteristics of humanblocking antibody. J Immunol 1968;101:317–324.
51.
Aalberse RC, Gaag R, Leeuwen J: Serologic aspects of IgG4antibodies. I. Prolonged immunization results in an IgG4–restricted response. JImmunol 1983;130:722–726.
52.
Birkner T, Rumpold H, Jarolim E, Ebner H, Breitenbach M, Skvaril F,Scheiner O, Kraft D: Evaluation of immunotherapy–induced changes in specific IgE,IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Allergy1990;45:418–426.
53.
Menz G, Dolecek C, Schönheit–Kenn U, Ferreira F,Moser M, Schneider T, Suter M, Boltz–Nitulescu G, Ebner C, Kraft D, Valenta R:Serological and skin–test diagnosis of birch pollen allergy with recombinant Bet v 1,the major birch pollen allergen. Clin Exp Allergy 1996;26:50–60.
54.
Pauli G, Oster JP, Deviller P, Heiss S, Bessot J, Susani M, FerreiraF, Kraft D, Valenta R: Skin testing with recombinant allergens rBet v 1 and rBet v 2.Diagnostic value for birch pollen and associated allergies. J Allergy Clin Immunol1996;97:1100–1109.
55.
Vrtala S, Susani M, Sperr WR, Valent P, Laffer S, Dolecek C, KraftD, Valenta R: Immunologic characterization of purified recombinant timothy grass pollen(Phleum pratense) allergens (Phl p 1, Phl p 2, Phl p 5). J Allergy Clin Immunol1996;97:781–787.
56.
Tame A, Sakiyama Y, Kobayashi I, Terai I, Kobayashi K: Differencesin titres of IgE, IgG4 and other IgG subclass anti–Der p 2 antibodies in allergic andnon–allergic patients measured with recombinant allergen. Clin Exp Allergy1996;26:43–49.
57.
Kobayashi I, Sakiyama Y, Tame A, Kobayashi K, Matsumoto S: IgEand IgG4 antibodies from patients with mite allergy recognize different epitopes ofDermatophagoides pteronyssinus group II antigen (Der p 2). J Allergy Clin Immunol1996;97:638–645.
58.
Valenta R, Ball T: Antibody recognition of recombinant allergens andallergen fragments: Evidence for a predominantly direct class switch to IgE in allergicpatients, in Vercelli D (ed): IgE Regulation: Molecular Mechanisms. Chichester, Wiley, 1997,pp 225–236.
59.
Vrtala S, Ball T, Spitzauer S, Pandjaitan B, Suphioglu C, Knox B,Sperr WR, Valent P, Kraft D, Valenta R: Immunization with purified natural and recombinantallergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE,inhibit the human IgE–allergen interaction and allergen–induced basophildegranulation. J Immunol, in press.
60.
Smith AM, Chapman MD: Reduction in IgE binding to allergenvariants generated by site–directed mutagenesis: Contribution of disulfide bonds. MolImmunol 1996;33:399–406.
61.
Noguchi E, Shibasaki M, Nishiyama C, Okumura Y, Takita H: IgEresponsiveness to Dermatophagoides farinae in young asthmatic children: IgE binding studyusing recombinant allergens of Der f 1, Der f 2 and mutant proteins of Der f 2. Int ArchAllergy Immunol 1996;110:380–387.
62.
Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, Mori A, OkudairaH, Okumura Y: Engineering of the major house dust mite allergen Der f 2 forallergen–specific immunotherapy. Nat Biotechnol 1997;15:754–758.
63.
Ferreira F, Hirtenlehner K, Jilek A, Godnick–Cvar J,Breiteneder H, Grimm R, Hoffmann–Sommergruber K, Scheiner O, Kraft D,Breitenbach M, Rheinberger HJ, Ebner C: Dissection of immunoglobulin E and T lymphocytereactivity of isoforms of the major birch pollen allergen Bet v 1: Potential use ofhypoallergenic isoforms for immunotherapy. J Exp Med 1996;183:599–609.
64.
Kolbe L, Heusser CH, Kolsch E: Isotype–associatedrecognition of allergen epitopes and its modulation by antigen dose. Immunology1995;84:285–289.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.